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Abstract
Purpose The objective of this study was to evaluate the
current utilization, the level of endorsement by professional
societies, and health technology assessment bodies, as well as
the reimbursement levels for bariatric surgery in European
countries.
Materials and Methods We performed an analysis of the
indications for bariatric surgery based on national clinical
and commissioning guidelines, current utilization of surgery,
characteristics of patients who underwent surgery, and reim-
bursement tariffs in Belgium, Denmark, England, France,
Germany, Italy, and Sweden. Data were obtained from nation-
al patient registries, administrative databases, and published
literature for the year 2012.
Results Despite clear consensus outlined in clinical guide-
lines, significant differences were found in the eligibility
criteria for surgery. Patients with no significant comorbidities
were deemed eligible if they had a body mass index (BMI) of
40 or 50 kg/m2 in Denmark. Irrespective of the country,
patients with comorbidities were eligible if they had a BMI
of 35 kg/m2. The highest utilization of bariatric surgery (num-
ber of surgeries per 1 M population) was observed in Belgium
(928), Sweden (761), and France (571) while Italy (128),
England (117), and Germany (72) had the lowest utilization.
There was a strong negative correlation between utilization
and average BMI level of the patient population (r=−.909, p=
0.005). The annual per capita spending on surgery differed
significantly between countries, ranging from €0.54 in Ger-
many to €4.33 in Belgium.
Conclusions There are significant variations in the clinical
indications, utilization, and funding of bariatric surgery in
European countries.
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Introduction/Purpose
Bariatric surgery is highly effective for patients with severe
obesity who fail to achieve sustained weight loss with con-
ventional treatments. Although there is agreement regarding
the clinical indications for surgery, little is known about the
relative use of bariatric surgery in European countries. The
objectives of this study were to evaluate and compare the
current use of bariatric surgery, the degree of endorsement
by professional societies, and health technology assessment
bodies, as well as the level of reimbursement.
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Materials and Methods
We analyzed the indications for bariatric surgery, current use
of surgery, characteristics of patients undergoing surgery, and
reimbursement tariffs from seven European countries (Bel-
gium, Denmark, England, France, Germany, Italy, and
Sweden).
Information regarding the clinical indications was obtained
from national clinical and commissioning guidelines for obe-
sity and bariatric surgery. Bariatric surgical patients’ clinical
characteristics were retrieved from patient registries (the Dan-
ish Bariatric Surgery Registry for Denmark, the Scandinavian
Obesity Surgery Registry for Sweden, and the National Bar-
iatric Surgery Registry for the United Kingdom), large nation-
al studies (France [1] and Germany [2]), and large single-
center reports (Belgium [3] and Italy [4]).
Data on the annual number of adjustable gastric banding,
gastric bypass, and sleeve gastrectomy surgeries were obtain-
ed from patient registries for Denmark (2012), Italy (2012),
and Sweden (2012). Data for Belgium, France, Germany, and
England were obtained from national administrative databases
that included the Belgian Technical Unit for Analysis of
Hospital Data (2010), the French Technical Agency for Hos-
pitalization Information (2012), Hospital Episode Statistics
for England (2011–2012), and the German Diagnostic-
Related Group (DRG) data (2011). For England and Germany,
a combination of procedure and diagnosis codes was used to
estimate the number of surgical procedures performed (Table 1).
For France, only the procedure codes were used. For Belgium,
the number of patient cases in the All Patient Reported DRG
system for 2010 was used as a proxy for the number of surgical
procedures. Data about number of procedures were obtained
only for residents of the country, where possible. The rates of
all surgical procedures per 1 million (M) population were
calculated using population size data from the Organization
for Economic Cooperation and Development [5]. The preva-
lence of obesity in the adult population was obtained from the
World Health Organization [6].
Pearson’s product-moment correlation, Spearman’s rank-
order correlation, and linear regression were performed to
assess the relationship between the number of surgeries per-
formed annually (per 1 M population) and the average BMI,
the prevalence of comorbidities in patients undergoing sur-
gery, and the obesity prevalence.
Interrupted time series analysis using autoregressive inte-
grated moving average and time series regression techniques
were performed to evaluate the impact of the new 2010
guidelines for the use of bariatric surgery in Denmark [7].
An estimate of the number of surgeries performed in 2013was
obtained from experts in the field. But because of the limited
number of observations available between 2007 and 2013,
autoregression was not possible. Statistical analysis was per-
formed using SPSS version 20 (IBM Corp., Armonk, New
York, USA).
Reimbursement tariffs for each country were obtained
through their respective national DRG by combining the
relevant procedure and diagnosis codes in the grouping soft-
ware (for Denmark, France, Germany, Sweden, and England)
[8–12]. For Italy, relevant DRG code was found in national
clinical guidelines [13]. For Belgium, the value for the rele-
vant tariff in the All Patient Refined DRG Project was avail-
able only for 2010. The total annual spending on bariatric
surgery was estimated by multiplying the relevant averaged
national public tariff and the number of surgeries performed.
In France, separate tariffs for public and private providers
were applied. A weighted average was obtained for the tariff
for each surgical technique, and all cost data are presented in
2012 Euros.
Results
Clinical Indications
Table 2 shows a summary of the clinical indications for
bariatric surgery. With the exception of Denmark and
Table 1 Procedure and disease codes used for the estimation of bariatric surgery volume
Country Procedure codes Diagnosis codes DRG
codes
Belgium – – APR
DRG
403
France HFFA011, HFFC018, HFCC003, HFCA001, HFMA009, HFMC007, HFKA002, HFKC001 – –
Germany 5–434.50, 5–434.51, 5–434.52, 5–436.11, 5–445.01, 5–445.02, 5–445.10, 5–445.11, 5–445.12, 5–
445.20, 5–445.21, 5–445.22, 5–445.40, 5–445.41, 5–445.42, 5–445.50, 5–445.51, 5–445.52, 5–
445.×1, 5–445.x2, 5–445.×3, 5–448.b0, 5–448.b1, 5–448.b2, 5–448.bx, 5–448.c0, 5–448.c1, 5–
448.c2, 5–448.c3, 5–448.cx
E66, E66.0, E66.1, E66.2,
E66.8, E66.9
–
England G28.1, G28.2, G28.3, G28.4, G28.5, G28.8, G28.9, G30.1, G30.2, G30.3, G31.0, G31.1, G31.2,
G31.4, G31.6, G31.8, G31.9, G32.0, G32.1, G32.3, G32.4, G32.5, G32.8, G32.9, G33.0, G33.1,
G33.3, G33.5, G33.6, G33.8, G33.9, G5.11
E66 –
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England, the entry BMI level for surgery for patients with no
serious comorbidities is 40 kg/m2. In Denmark, clinical guide-
lines recommend surgery at a BMI of 40 kg/m2, while
commissioning guidelines determine reimbursement only for
patients with a BMI of ≥50 kg/m2. In England, the entry BMI
level for surgery is 40 kg/m2 with requirements for an inten-
sive weight loss program for at least 12–24 months (6 months
for those with BMI>50 kg/m2). For patients with
comorbidities, the minimum BMI was 35 kg/m2 for all coun-
tries, although in England, this group of patients must still
undertake an intensive weight loss program for 12–24months.
The most common comorbidities include type 2 diabetes (all
countries), hypertension (all countries except Sweden), knee
osteoarthritis (Denmark, France, Italy, Sweden, and England),
and obstructive sleep apnoea (Belgium, Denmark, France, and
Sweden).
Table 2 National guidance for bariatric surgery
Country BMI level, kg/m2 Comorbidities Requirements for conservative treatment
prior to bariatric surgery
Source
Without
comorbidities
With
comorbidities
Belgium 40 35 T2DM, hypertension, OSA Not available [14]
Denmark 40 35 T2DM, hypertension, OSA,
PCOS, knee osteoarthritis
Sustainable weight loss not achieved by conventional treatment [15]
50 35 [16]
England 40 35 T2DM, hypertension, OSA,
knee osteoarthritis
Failure of non-surgical methods for at least 6 months [17]
50 Bariatric surgery is recommended as a first-line treatment option
40 Weight loss programme for 12–24 months [18]
50 Weight loss programme for 6 months minimum
France 40 35 T2DM, hypertension, OSA,
knee osteoarthritis
Failure of nutritional, dietary and medical treatment;
psychotherapy conducted for 6–12 months; absence of
sufficient weight loss or lack of maintenance of weight loss
[19]
Germany 40 35 T2DM, hypertension Failure of conservative management [20]
Italy 40 35 T2DM, hypertension, knee
osteoarthritis, severe
psychological problems
Failure of proper medical treatment including inadequate weight
loss or poor maintenance of weight loss
[13]
Sweden 40 35 T2DM, OSA, pregnancy issues,
knee osteoarthritis
Failure of weight loss using non-surgical methods [21]
BMI body mass index, OSA obstructive sleep apnea, PCOS polycystic ovary syndrome, T2DM type 2 diabetes
Table 3 Comparison of clinical indications and characteristics of the patient population who underwent bariatric surgery
Country Cohort BMI level with no comorbidities BMI level with at least comorbidity Prevalence of comorbidities
T2DM Hypertension OSA Knee osteoarthritis
Belgium Indication 40 35 Yes Yes Yes No
Real cohort 38 9 % 28 % 3 % NA
Denmark Indication 40/50 35 Yes Yes Yes Yes
Real cohort 45 23 % 32 % 11 % NA
England Indication 40/50 35 Yes Yes Yes Yes
Real cohort 50.6 24 % 32 % 16 % 53 %
France Indication 40 35 Yes Yes Yes Yes
Real cohort 43.7 10 % 22 % 12 % NA
Germany Indication 40 35 Yes Yes No No
Real cohort 48.8 20 % 57 % 21 % 44 %
Italy Indication 40 35 Yes Yes No Yes
Real cohort 46.2 NA NA NA NA
Sweden Indication 40 35 Yes No Yes Yes
Real cohort 42.8 18 % 43 % 9 % NA
BMI body mass index, NA not available, OSA obstructive sleep apnea, T2DM type 2 diabetes
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Patient Characteristics
A comparison of the clinical indications and patient charac-
teristics for bariatric surgery is shown in Table 3.
There was a strong negative correlation between the
number of surgeries performed annually (per 1 M popula-
tion) and the average patient BMI (r=−.909, p=0.005).
Figure 1 shows the linear regression analysis. There was
a moderate, but not statistically significant correlation
found between the number of surgeries performed annually
(per 1 M population) and the prevalence of obesity (r=
−.404, p=0.368) (Fig. 2 shows the linear regression anal-
ysis). There was a strong negative but not statistically
significant correlation between the number of surgeries
performed annually per 1 M population and the prevalence
of type 2 diabetes (r=−.793, p=0.060), a moderate nega-
tive but not statistically significant correlation with the
prevalence of hypertension (rs=−.522, p=0.228), and a
significant strong negative correlation with the prevalence
of obstructive sleep apnea (r=−.887, p=0.019).
Use and Funding of Bariatric Surgery
The use of the three most common bariatric surgeries in
2012 is shown in Fig. 3. Gastric bypass is the most
dominant procedure in all countries with the highest
use in Sweden (98 %), Denmark (96 %), and Belgium
(80 %). Gastric banding is used significantly only in
France (19 %), England (21 %), and Italy (37 %). Max-
imum surgical rates (per 1 M population) are found in
Belgium (928), Sweden (761), and France (571), while
the lowest rates are in England (117) and Germany (72).
Estimates of annual spending on bariatric surgery in 2012
are shown in Table 4. Per capita spending on bariatric surgery
differs more than eight times between the countries with the
lowest and the highest spending, ranging from €0.54 in Ger-
many to €4.33 in Belgium.
Summary of Appraisal, Commissioning, and Quality
Assurance for Bariatric Surgery in European Countries
Belgium
There are no national clinical guidelines for bariatric
surgery in Belgium. In 2006, the Belgian Health Care
Knowledge Centre issued a report that confirmed the
effectiveness and cost-effectiveness of surgery versus
nonsurgical treatment [14]. There is no national quality
registry for bariatric surgery currently in place in Bel-
gium, and since the Health Care Knowledge Centre
report was published, no other national reviews on the
status of bariatric surgery have been presented.
Fig. 1 Linear regression for the
annual number of surgeries per
1 M population and the average
BMI level of the patient
population who underwent
surgery
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Denmark
In 2007, the Danish Centre for Health Technology Assess-
ment issued a report on bariatric surgery that supported the use
of gastric bypass and gastric banding [22]. Recommendations
for surgery provision were issued in 2008 under the supervi-
sion of the National Board of Health [15]. In 2010, based on a
review of the use of bariatric surgery in Denmark, the Danish
Regions issued new, stricter guidelines for bariatric surgery
[16]. The rationale included the overuse of surgery in patients
with fewer comorbidities, the rapid increase in the number of
surgeries, and the high complication rate. The goal of the
treatment guidelines was to reduce the number of surgeries
by 40 % to provide resources for treatment in other areas.
Interrupted time series analysis showed that the number of
bariatric surgeries decreased significantly in 2010 following
changes to the clinical indications (Fig. 4). The guidelines
reduced the number of procedures by 2879 after 1 year (standard
error 566, 95 % confidence interval 444–5314 cases). Details of
the analysis are provided in the Supplemental Material.
Between 2010 and 2012, although the prevalence of co-
morbidities increased slightly (5% for type 2 diabetes, 4 % for
hypertension, and 3 % for obstructive sleep apnoea) [23–25],
the average patient BMI remained the same at 45 kg/m2, but
the median decreased to 44 kg/m2. A high-quality registry for
bariatric surgery has been implemented at the Danish national
level since 2010, which annually monitors performance using
eight indicators [26].
Fig. 2 Linear regression for the
annual number of surgeries per
1 M population and the
prevalence of obesity (percentage
of population) in each country
Fig. 3 Number of bariatric
surgeries performed in European
countries. Note: types of surgery
are plotted against the left vertical
axis. Circles represent number of
surgeries per 1 million of the
population in each country and
are plotted against the right
vertical axis
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France
The national health technology assessment body, the French
National Authority for Health, issued recommendations for
bariatric surgery in 2009 [19]. In 2007, national bariatric
surgery was established under the umbrella of the French
and French-speaking Society of Obesity Surgery, although
general reports from the registry are not available. In general,
the clinical and policy environment is favorable toward bar-
iatric surgery.
Germany
The value of bariatric surgery in Germany was evaluated in
2008 by the German Institute of Medical Information and
Documentation [27]. Despite acknowledgement of the short-
Table 4 Spending on bariatric surgery
Country Type of
surgery
Weighted average
reimbursement
tariffs, €
DRG group Specificity of DRG in
relation to different
types of surgery
Specificity of
DRG in relation to
complications
Total spending on
bariatric surgery,
€ million
Total per capita
spending, €
Belgium All types 4668 APR-DRG 403 Non-specific Non-specific 48 4.33
Denmark GBP 4327 DRG 1004 Non-specific Non-specific 5 0.98
SG 3742 DRG 2601
GB 4327 DRG 1004
England GBP 5999 FZ04A, FZ04B Specific Specific (2 levels
of severity)
33 0.62
SG
GB 2792 FZ05A, FZ05B Specific (2 levels
of severity)
France GBP 7314 10C13 Specific Specific (4 levels
of severity)
243 3.77
SG 7314 10C13
GB 3524 10C09+Nomenclature
tariff for band
Germany GBP 7667 K04A Specific Non-specific 44 0.54
SG 7667 K04A
GB 5725 K04B
Italy All types 5681 DRG 288 Non-specific Non-specific 43 0.73
Sweden GBP 5012 L08E, L08C, L08A Non-specific Specific (3 levels
of severity)
36 3.81
SG
GB
SG
GB 2792 FZ05A, FZ05B Specific (2 levels
of severity)
GB gastric banding, GBP gastric bypass, SG sleeve gastrectomy
Fig. 4 Number of bariatric
surgeries performed in Denmark
between 2007 and 2013. Note: the
black line indicates when the
clinical indications were changed
(2010, effective from 2011)
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and mid-term effectiveness as well as the cost-effectiveness of
bariatric surgery, the evaluators recommended restricted reim-
bursement. Currently, there is an ongoing national quality
assurance study on the safety and efficacy of bariatric surgery
although follow-up is limited to 1 year [2]. The most recent
German clinical guidelines were issued in 2009. In general,
bariatric surgery is well accepted by the medical community,
but a bottleneck in patient care is created by the insurance
companies, which require extensive and not well-defined pre-
surgical conservative treatments.
Italy
In 2008, the Italian Society of Obesity andMetabolic Diseases
issued clinical guidelines and a state-of-the-art report [13].
Regional inequalities accessing surgery and an unbalanced
reimbursement tariff were among the barriers for broader
implementation of bariatric surgery. Reimbursement tariffs
for bariatric surgery also differed significantly between re-
gions. The Italian Society of Obesity and Metabolic Diseases
maintains a national registry of bariatric surgery [28].
Sweden
In 2002, the Swedish Council on Health Technology Assess-
ment produced a report on the treatment of obesity and con-
cluded that “in people with severe obesity, surgical treatment
has positive, well-documented long-term effects on weight,
quality of life, and morbidity from diabetes” [29]. In 2008, a
mini-health technology appraisal was performed in one of the
Swedish regions (Region Västra Götaland), which concluded
that there was good evidence for weight loss effect and rea-
sonable safety compared with other procedures, but limited
evidence for the impact on mortality and diabetes [30]. The
latest clinical indications for bariatric surgery were established
in 2011 [21]. Sweden has hosted a comprehensive, high-
quality Scandinavian Obesity Surgery Registry since 1998
[31] that includes routine 2-year follow-up following the
surgical procedure. Despite a favorable environment, the
number of cases has decreased slightly in 2013 compared with
2011–2012.
United Kingdom/England
In the UK, the economic value of bariatric surgery was eval-
uated in a number of studies: a health technology assessment
report in 2008 [32], an economic report by the Office of
Health Economics [33], and a short appraisal in Scotland in
2012 [34]. Bariatric surgery was shown to be effective, rea-
sonably safe, and cost-effective (cost saving analysis from a
societal perspective) in UK settings. The National Institute of
Clinical and Care Excellence issued the latest clinical guide-
lines on obesity in 2006, which endorsed bariatric surgery. On
1 April 2013, the National Health Services in England took
over commissioning of bariatric surgery from the primary care
setting and added a supplementary requirement for all patients
to undergo a 12–24-month (6 months for BMI≥50 kg/m2)
“Tier 3” lifestyle intervention program in the community
before being referred for bariatric surgery [18]. A review by
the English Health and Social Care Information Centre
showed that the number of bariatric surgeries decreased by
8.8 % from 2012 to 2013 compared with 2011–2012 [35]. A
further downturn in bariatric surgery is expected for 2013–
2014 as prospective patients get diverted to Tier 3 programs
before surgery.
Conclusions
This study provides an overview of the indications, use, and
funding of bariatric surgery in patients from seven European
countries. Our analysis has highlighted several significant
differences between countries.
The indications for bariatric surgery differ significantly
among countries despite strong agreement on the clinical
guidelines. Interestingly, with increase of utilization of surgery
BMI level is lowering, which illustrates inclusion of broader
group of patients, although in all countries, indication remains
within recommended limit. Despite the availability of sub-
stantial evidence for the safety and efficacy of bariatric sur-
gery, reimbursement recommendations in Denmark for the
coverage of surgery were changed, raising the BMI entry level
to 50 kg/m2, while England has insisted on mandatory preop-
erative weight loss programs for which no supporting evi-
dence exists. These changes are not consistent with the current
evidence demonstrating the clinical benefit of bariatric surgery
in patients with morbid obesity. If left untreated, these patients
have significant unmet needs and careful consideration of the
clinical, and economic impact of policy changes is required.
The Danish example particularly demonstrates, on one
hand, the example of data-driven decision-making in bariatric
surgery, but on the other hand, the lack of comprehensive and
rational evidence-based disinvestment policy in health care in
general across different disease areas. This means that as
health care systems operate under substantial resource con-
straints, for sustainability of a system, it is required to consider
both investment (reimbursement of new treatment methods)
and disinvestment (termination of reimbursement of noneffec-
tive or noncost-effective methods). Tightening reimbursement
criteria for bariatric surgery is some form of disinvestment,
which, first, should be based on solid scientific ground and,
second, should be based on comparison of benefits and costs
of bariatric surgery with health care intervention in other
clinical areas. In different European countries, bariatric sur-
gery was found to be either very cost-effective or cost-saving
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[32, 36–40] and, in general, more cost-effective compared
with many technologies in health care. This was supported
by an analysis of potential efficiency gains that used cost-
effectiveness evidence to reallocate Medicare expenditures in
the USAwhere bariatric surgery was considered worth prior-
itization in comparison with many other services [41].
In our analysis, the highest use of bariatric surgery was
observed in Belgium, Sweden, and France. As a total spend-
ing per capita, these three countries also had the highest level
of spending on bariatric surgery. Moreover, high utilization of
surgery is not explained by medical tourism, for example, in
Belgium, which was not included into analysis. Nevertheless,
in all countries, even with a high level of surgery use, the
provision of care is still far below demand. Indeed, a recent
English study estimated that more than two million people
were eligible for surgery according to the National Institute for
Care and Clinical Excellence indications, but the actual annual
number of surgeries was <10,000 cases [42]. What is the
optimal use of bariatric surgery in the current reimbursement
and clinical environment? Based on our comparative analysis
of seven European countries, the Swedish model may be the
ideal. It includes clinical indications based on a comprehen-
sive health technology assessment process, the specificity of
reimbursement tariffs, regular tariff updates, a tight and com-
prehensive quality assurance program that prevents the over-
use and reduction of the quality of surgery, the lack of addi-
tional barriers from service commissioners, the understanding
of the relative value of surgery and conservative methods by
the medical community, and a correlation between the clinical
indications and patient characteristics.
There are several limitations to our study. We considered
only three of the most common surgical techniques, and the
inclusion of other surgeries might have changed the numbers
for surgery use.We did not perform a comparison of outcomes
of bariatric surgery in different countries as the efficacy and
outcomes might depend highly on patient case mix, the num-
ber of hospitals involved, and other factors.
There are significant variations in the clinical indications,
use, and funding of bariatric surgery in European countries.
The update and revision of current clinical recommendations,
based on the latest evidence available, are required to ensure
optimal access to effective treatment options.
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